Hokkaido University – BIO International Convention 2026
2026.06.11
Hokkaido University will be participating BIO International Convention 2026, the world's largest biotechnology partnering event, to be held in San Diego, California, USA, from June 22–25, 2026.
Official website: BIO International Convention | June 22-25 | San Diego
Representatives from Hokkaido University in the fields of life sciences and biotechnology will share the University’s latest research achievements and technological innovations to explore the partnering opportunities including patent licensing and collaborative research with leading companies worldwide.
Through participation in BIO International Convention 2026, Hokkaido University seeks to further promote international research exchange and contribute to the advancement of biopharmaceutical science and innovation.
Assets: Hokkaido University Bio International 2026
Platform & Other Therapeutics
1, GFRα1: A First-in-Class Lead for Functional CNS and PNS Nerve Regeneration
2, p3-Alcβ9-19: A Primate-Validated, Brain-Penetrant Mitochondrial Activator for AD
3, Targeted RNA Chaperones: A Precise Mechanism to Protect Motor Neurons in ALS
4, NET Inhibitors: Accelerating Acute Nerve Repair via the MIF/CXCR4 Axis
5, HSC-Targeted LNPs: A Precision Delivery Platform for Reversing Hepatic Fibrosis
6, Spleen-Specific LNPs: Optimized Dendritic Cell Delivery for Next-Gen Vaccines
7, Helper Lipids: A Potency-Boosting Solution for Enhanced Endosomal Escape
8, Novel ζ-Lipids for Cas9 RNP Delivery: 98% Gene Knockout in vivo
9, NK Cell-Specific LNPs: Scalable Genetic Modification for Cold Tumor Therapy
10, Novel Cationic Lipids for Extrahepatic Delivery
23, srRNA: A Stable, Vector-Based Alternative for Exon-Skipping Therapies
24, MITO-Porter & CRISPR/Cas9: An Advanced Platform for Mitochondrial Gene Editing
25, IL-34-Induced Macrophages: Autologous Cell Therapy for Advanced Liver Cirrhosis
26, Resolvin E3 Indoles: A Pro-Resolving Approach for Insulin Resistance
27, Syk Inhibitors: A Safety Bridge for Post-Denosumab Transition in Osteoporosis
28, BDNF-Inducing Peptides: A Neuroprotective Approach for Glaucoma Treatment, Complementing IOP-lowering therapy
29, Selective Senolytics: Removing Senescent Cells to Reverse UV-Induced Skin Aging
30, Neutralizing mAbs for Marburg Virus: High-Potency Outbreak Control Tools
31, Universal Pan-Species Ebola Antibodies: A Cross-Neutralizing Therapeutic Lead
32, Nemuri-Derived Peptides: A New Line of Defense Against MDR Bacterial Pathogens
33, 2-thiouridine (s2U): A Broad-Spectrum Antiviral for Positive-Strand RNA Viruses
34, Bioluminescent BLI Mice: Real-Time evaluation for Reproductive Toxicity
2, p3-Alcβ9-19: A Primate-Validated, Brain-Penetrant Mitochondrial Activator for AD
3, Targeted RNA Chaperones: A Precise Mechanism to Protect Motor Neurons in ALS
4, NET Inhibitors: Accelerating Acute Nerve Repair via the MIF/CXCR4 Axis
5, HSC-Targeted LNPs: A Precision Delivery Platform for Reversing Hepatic Fibrosis
6, Spleen-Specific LNPs: Optimized Dendritic Cell Delivery for Next-Gen Vaccines
7, Helper Lipids: A Potency-Boosting Solution for Enhanced Endosomal Escape
8, Novel ζ-Lipids for Cas9 RNP Delivery: 98% Gene Knockout in vivo
9, NK Cell-Specific LNPs: Scalable Genetic Modification for Cold Tumor Therapy
10, Novel Cationic Lipids for Extrahepatic Delivery
23, srRNA: A Stable, Vector-Based Alternative for Exon-Skipping Therapies
24, MITO-Porter & CRISPR/Cas9: An Advanced Platform for Mitochondrial Gene Editing
25, IL-34-Induced Macrophages: Autologous Cell Therapy for Advanced Liver Cirrhosis
26, Resolvin E3 Indoles: A Pro-Resolving Approach for Insulin Resistance
27, Syk Inhibitors: A Safety Bridge for Post-Denosumab Transition in Osteoporosis
28, BDNF-Inducing Peptides: A Neuroprotective Approach for Glaucoma Treatment, Complementing IOP-lowering therapy
29, Selective Senolytics: Removing Senescent Cells to Reverse UV-Induced Skin Aging
30, Neutralizing mAbs for Marburg Virus: High-Potency Outbreak Control Tools
31, Universal Pan-Species Ebola Antibodies: A Cross-Neutralizing Therapeutic Lead
32, Nemuri-Derived Peptides: A New Line of Defense Against MDR Bacterial Pathogens
33, 2-thiouridine (s2U): A Broad-Spectrum Antiviral for Positive-Strand RNA Viruses
34, Bioluminescent BLI Mice: Real-Time evaluation for Reproductive Toxicity
Oncology
11, PIECE Platform Technology targeting Intracellular IL-6 for Tumor Therapeutics
12, Anti-IL-34 mAbs: Strategic Add-ons to Overcome Therapeutic Resistance
13, DCA-Micelles: A Precision Metabolic Radiosensitizer for Local Tumor Control
14, Drug Discovery Targeting the BATF3/IRF4 Axis Enabling Indication Expansion Beyond ATLL
15, A Novel Therapeutic Strategy for HCC Targeting Tumor Metabolic Transporters
16, Retinoid Pathway-Targeted Therapy for Synovial Sarcoma
17, Dual MCT1/MCT4 Inhibition Strategy for Hypoxia-Resistant Hepatocellular Carcinoma
12, Anti-IL-34 mAbs: Strategic Add-ons to Overcome Therapeutic Resistance
13, DCA-Micelles: A Precision Metabolic Radiosensitizer for Local Tumor Control
14, Drug Discovery Targeting the BATF3/IRF4 Axis Enabling Indication Expansion Beyond ATLL
15, A Novel Therapeutic Strategy for HCC Targeting Tumor Metabolic Transporters
16, Retinoid Pathway-Targeted Therapy for Synovial Sarcoma
17, Dual MCT1/MCT4 Inhibition Strategy for Hypoxia-Resistant Hepatocellular Carcinoma
Immunology / Inflammation
18, Epigenetic Modulator for Refractory GVHD and IBD
19, Next-Gen STING Agonists: Converting Cold Tumors via Potent Systemic Activation
20, STAP-1 Peptides: Selective T-Cell Modulation for Precision Autoimmune Therapy
21, Restoring NET Degradation in ANCA Vasculitis Discovery
22, Meflin: A Novel Biomarker and Therapeutic Target for Systemic Inflammation
19, Next-Gen STING Agonists: Converting Cold Tumors via Potent Systemic Activation
20, STAP-1 Peptides: Selective T-Cell Modulation for Precision Autoimmune Therapy
21, Restoring NET Degradation in ANCA Vasculitis Discovery
22, Meflin: A Novel Biomarker and Therapeutic Target for Systemic Inflammation
Technologies
35, Enhanced Mammalian Cell Vectors: High-Yield Production of Bio-Active Proteins
38, Micro-Scale SAR Platform: Rapid Structure-Optimization for Peptide Leads
39, Nonribosomal Peptide Cyclases: A High-Throughput Engine for Cyclic Peptide Discovery
38, Micro-Scale SAR Platform: Rapid Structure-Optimization for Peptide Leads
39, Nonribosomal Peptide Cyclases: A High-Throughput Engine for Cyclic Peptide Discovery
Medtech
36, IgA N-Glycan Markers: A Non-Invasive Diagnostic Tool for MASH Fibrosis Stages
37, HD5 Diagnostic Kits: Precision Monitoring for Intestinal Health and Microbiome
40, Portable Parasite NGS: A Field-Ready Comprehensive Detection System
41, Ultra-Sensitive Immunoassay Platform Using Advanced Optical Sensing
42, Attachment for Microscope Objective Lenses and Microscope
43, Non-Invasive taVNS Device: A Neuromodulation Strategy for Interstitial Pneumonia
44, Biomimetic Artificial Cartilage Implant for Durable Joint Repair
45, Cation-π Polymer Embolic Agent: Safe, Injectable, and Stable Vessel Occlusion
37, HD5 Diagnostic Kits: Precision Monitoring for Intestinal Health and Microbiome
40, Portable Parasite NGS: A Field-Ready Comprehensive Detection System
41, Ultra-Sensitive Immunoassay Platform Using Advanced Optical Sensing
42, Attachment for Microscope Objective Lenses and Microscope
43, Non-Invasive taVNS Device: A Neuromodulation Strategy for Interstitial Pneumonia
44, Biomimetic Artificial Cartilage Implant for Durable Joint Repair
45, Cation-π Polymer Embolic Agent: Safe, Injectable, and Stable Vessel Occlusion